Skip to Content

Jason B. Fleming, M.D., F.A.C.S.

Present Title & Affiliation

Primary Appointment

Professor w/Tenure, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Fleming is a pancreatic surgeon at MD Anderson and serves as director of the tissue acquisition and biorepository core for the Pancreas Cancer Research Program at MD Anderson. Dr. Fleming initiated and developed the first direct xenograft program in GI cancer at MD Anderson. These are derived from human pancreatic adenocarcinomas that Dr. Fleming and his surgical colleagues surgically remove from patients at MD Anderson. Direct xenografts recapitulate the tumor microenvironment and provide a unique platform to examine pancreatic adenocarcinoma.

Office Address

The University of Texas MD Anderson Cancer Center
1400 Pressler Street
Unit Number: 1484
Houston, TX 77030
Room Number: FCT17.5048
Phone: 713-745-0890
Fax: 713-745-4426

Education & Training

Degree-Granting Education

1990 University of Tennessee Center of Health Science, Memphis, TN, MD, Doctor of Medicine
1986 Vanderbilt University, Nashville, TN, BS, Molecular Biology

Postgraduate Training

7/1997-6/1999 Clinical Fellowship, Surgical Oncology Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX, Raphael E. Pollock, M.D.
7/1993-6/1995 Research Fellowship, Cancer Research Fellowship, University of Texas Southwestern Medical Center, Hamon Center for Therapeutic Oncology, Dallas, TX, John D. Minna, M.D.
7/1990-6/1997 Clinical Residency, General Surgery, University of Texas Southwestern Medical Center, Dallas, TX, C. James Carrico, M.D.

Board Certifications

2/1998 American Board of Surgery Certification, Recertification Date: 12/2008


Academic Appointments

Associate Professor w/Tenure, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006-2012
Associate Professor w/Tenure, Surgery, Surgical Oncology, The University of Texas Southwestern Medical Center, Dallas, TX, 2005-2006
Graduate Faculty, Integrative Biology and Cancer Biology Programs, Basic Science, The University of Texas Southwestern Graduate School of Biomedical Sciences, Dallas, TX, 2002-2006
Assistant Professor, The University of Texas Southwestern Medical Center, Dallas, TX, 1999-2005

Administrative Appointments/Responsibilities

Director, Perioperative Services, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2014-present
Chief, Section on Pancreas Surgery, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2009-present
Program Director, Surgical Oncology Fellowship, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2009-6/2014
Program Director, International Surgical Oncology Fellowship, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2009-6/2014

Other Appointments/Responsibilities

Member, Dan L. Duncan Cancer Center at Baylor College of Medicine, Data and Safety Monitoring Board (DSMB), Houston, TX, 9/2011-present

Honors and Awards

2012-present Guide to America's Top Surgeons, Consumer Research Council of America
2012-present Texas Super Doctors 2011, Texas Monthly, December
2011-2012 Texas Super Doctors 2011, Texas Monthly, December
2009 Outstanding Teaching Award, UT MD Anderson Cancer Center, Surgical Oncology
2008 J Bradley Aust Award, Western Surgical Society
1989 Alpha Omega Alpha, Alpha Omega Alpha Fraternity

Professional Memberships

Alpha Omega Alpha Fraternity
Member, 1989
American Association for Cancer Research
Member, 2003-present
American Board of Surgery Certifying Examination, Dallas, TX
Associate Examiner, 2010-present
American Cancer Society
Member, 2001
American College of Surgeons
Fellow, F.A.C.S, 2003
American Medical Association
Member, 1990
American Society of Clinical Oncology (ASCO)
Member, 2002-present
American Surgical Association
Fellow, 2015-present
Association of Program Directors in Surgery
Member, 2002
Juvenile Diabetes Research Foundation, Greater Dallas Chapter, Dallas, TX
Board of Directors, 2002-present
North Texas Chapter of the American College of Surgeons
Member, 2000
Pancreas Cancer Action Network-AACR Pathway to Leadership Grant Scientific Review Committee
Member, 2014-2015
Member, 2013-2014
Medical Advisory Board, 2008-present
Member, 2008-present
Pancreas Club
Member, 2006-present
Parkland Surgical Society
Member, 1995
Society of Surgical Oncology (SSO)
Appointed Member, Education Council, 2011-2014
Scientific Committee, 2006-present
Member, 2002
Society of University Surgeons (SUS)
Member, 2003-present
Texas Medical Association
Expert Panel Member, 2005
Member, 1990
Western Surgical Society
Chair, 2013 Membership Committee, 2012-present
Member, 2013 Executive Committee, 2012-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, Abbruzzese JL, Chiao PJ. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 7(4):829-840, 2008. PMID: 18413796.
2. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26(18):3063-3072, 2008.
3. Katz MH, Hwang R, Fleming JB, Evans DB. Tumor-node-metastasis staging of pancreatic adenocarcinoma. CA Cancer J Clin 58(2):111-25, 2008. PMID: 18272835.
4. Hwang RF, Wang H, Lara A, Gomez H, Chang T, Sieffert N, Moon Y, Ram S, Zimmerman S, Lee JH, Pisters PW, Tamm EP, Fleming JB, Abbruzzese JL, Evans DB. Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer. Ann Surg Oncol 15(5):1356-66, 2008. PMID: 18256882.
5. Blazer DG, Ramirez PT, Wang H, Fleming JB. Distal pancreatectomy for isolated metastasis of endometrial carcinoma to the pancreas. JOP 9(1):56-60, 2008. PMID: 18182745.
6. Katz MH, Fleming JB, Pisters PW, Lee JE, Evans DB. Anatomy of the superior mesenteric vein with special reference to the surgical management of first-order branch involvement at pancreaticoduodenectomy. Ann Surg 248(6):1098-102, 2008. PMID: 19092356.
7. Crane CH, Varadhachary G, Settle SH, Fleming JB, Evans DB, Wolff RA. The integration of chemoradiation in the care of patient with localized pancreatic cancer. Cancer Radiother 13(2):123-43, 4/2009. PMID: 19167921.
8. Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, Varadhachary G, Abbruzzese JL, Crane CH, Krishnan S, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 16(4):836-47, 4/2009. PMID: 19194760.
9. Mummadi RR, Nealon WH, Artifon EL, Fleming JB, Bhutani MS. Pancreatic Schwannoma presenting as a cystic lesion. Gastrointest Endosc 69(2):discussion 341, 2/2009. PMID: 19185694.
10. Kim MP, Truty MJ, Choi W, Kang Y, Chopin-Lally X, Gallick GE, Wang H, McConkey DJ, Hwang R, Logsdon C, Abbruzzese JL, Fleming JB. Molecular profiling of direct xenograft tumors established from human pancreatic adenocarcinoma after neoadjuvant therapy. Ann Surg Oncol. e-Pub 6/2011. PMID: 21701930.
11. Wang J, Estrella JS, Peng L, Rashid A, Varadhachary GR, Wang H, Lee JE, Pisters PW, Vauthey JN, Katz MH, Gomez HF, Evans DB, Abbruzzese JL, Fleming JB, Wang H. Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Cancer 118(15):3801-11, 8/2012. PMID: 21735446.
12. Chatterjee D, Katz MH, Rashid A, Varadhachary GR, Wolff RA, Wang H, Lee JE, Pisters PW, Vauthey JN, Crane C, Gomez HF, Abbruzzese JL, Fleming JB, Wang H. Histologic grading the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: A predictor for patient outcome. Cancer 118(12):3182-90, 6/2012. PMID: 22028089.
13. Katz MH, Hu CY, Fleming JB, Pisters PW, Lee JE, Chang GJ. Clinical Calculator of Conditional Survival Estimates for Resected and Unresected Survivors of Pancreatic Cancer. Arch Surg. e-Pub 2/2012. PMID: 22351874.
14. Tzeng CW, Fleming JB, Lee JE, Xiao L, Pisters PW, Vauthey JN, Abdalla EK, Wolff RA, Varadhachary GR, Fogelman DR, Crane CH, Balachandran A, Katz MH. Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Therapy. Ann Surg Oncol 19(6):2045-53, 6/2012. PMID: 22258816.
15. Tzeng CW, Katz MH, Fleming JB, Pisters PW, Lee JE, Abdalla EK, Curley SA, Vauthey JN, Aloia TA. Risk of venous thromboembolism outweighs post-hepatectomy bleeding complications: analysis of 5651 National Surgical Quality Improvement Program patients. HPB (Oxford) 14(8):506-13, 8/2012. PMID: 22762398.
16. Weng S, Wang H, Chen W, Katz MH, Chatterjee D, Lee JE, Pisters PW, Gomez HF, Abbruzzese JL, Fleming JB, Wang H. Overexpression of Protein Phosphatase 4 Correlates with Poor Prognosis in Patients with Stage II Pancreatic Ductal Adenocarcinoma. Cancer Epidemiol Biomarkers Prev. e-Pub 6/2012. PMID: 22665577.
17. Thomas RM, Truty MJ, Nogueras-Gonzalez GM, Fleming JB, Vauhey JN, Pisters PW, Lee JE, Rice DC, Hofstetter WL, Wolff RA, Varadhachary GR, Wang H, Katz MH. Selective Reoperation for Locally Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma Following Primary Pancreatic Resection. J Gastrointest Surg 16(9):1696-704, 9/2012. PMID: 22644446.
18. Truty MJ, Thomas RM, Katz MH, Vauthey JN, Crane C, Varadhachary GR, Wolff RA, Abbruzzese JL, Lee JE, Fleming JB. Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration. J Am Coll Surg 215(1):41-51, 7/2012. PMID: 22608401.
19. Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, Wang H, Abbruzzese J, Pisters PW, Vauthey JN, Charnsangavej C, Tamm E, Crane CH, Balachandran A. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 118(23):5749-56, 12/2012. PMID: 22605518.
20. Suetsugu A, Katz M, Fleming JB, Truty M, Thomas R, Moriwaki H, Bouvet M, Saji S, Hoffman RM. Multi-color palette of fluorescent proteins for imaging the tumor microenvironment of orthotopic tumorgraft mouse models of clinical pancreatic cancer specimens. J Cell Biochem 113(7):2290-5, 7/2012. PMID: 22573550.
21. Abbott DE, Merkow RP, Cantor SB, Fleming JB, Varadhachary GR, Crane C, Bentrem DJ, Bilimoria KY. Cost-effectiveness of treatment strategies for pancreatic head adenocarcinoma and potential opportunities for improvement. Ann Surg Oncol 19(12):3659-67, 11/2012. PMID: 22965567.
22. Balachandran A, Tamm EP, Bhosale PR, Katz MH, Fleming JB, Yao JC, Charnsangavej C. Venous tumor thrombus in nonfunctional pancreatic neuroendocrine tumors. Am J Roentgenol 199(3):602-8, 9/2012. PMID: 22915400.
23. Petzel MQ, Parker NH, Valentine AD, Simard S, Nogueras-Gonzalez GM, Lee JE, Pisters PW, Vauthey JN, Fleming JB, Katz MH. Fear of cancer recurrence after curative pancreatectomy: A cross-sectional study in survivors of pancreatic and periampullary tumors. Ann Surg Oncol 19(13):4078-84, 12/2012. PMID: 22875648.
24. Katz MH, Lee JE, Pisters PW, Skoracki R, Tamm E, Fleming JB. Retroperitoneal dissection in patients with borderline resectable pancreatic cancer: Operative principles and techniques. J Am Coll Surg 215(2):e11-8, 8/2012. PMID: 22818108.
25. Saftoiu A, Bhutani MS, Vilmann P, Surlin V, Uthamanthil RK, Lee JH, Bektas M, Singh H, Gheonea DI, Patrascu S, Gupta V, Katz MH, Fleming JB. Feasibility Study of EUS-NOTES as a Novel Approach for Pancreatic Cancer Staging and Therapy: An International Collaborative Study. Hepatogastroenterology 60(121), 7/2012. PMID: 22776721.
26. Wisniewski WR, Fournier KF, Ling YK, Slack RS, Babiera G, Grubbs EG, Moore LJ, Fleming JB, You YN. A focused curriculum in surgical oncology for the third-year medical students. J Surg Res 185(2):555-60, 12/2013. e-Pub 7/2013. PMID: 23845865.
27. Tzeng CW, Katz MH, Lee JE, Fleming JB, Pisters PW, Vauthey JN, Aloia TA. Predicting the risks of venous thromboembolism versus post-pancreatectomy haemorrhage: analysis of 13 771 NSQIP patients. HPB (Oxford) 16(4):373-83, 4/2014. e-Pub 7/2013. PMCID: PMC3967890.
28. Philip B, Roland CL, Daniluk J, Liu Y, Chatterjee D, Gomez SB, Ji B, Huang H, Wang H, Fleming JB, Logsdon CD, Cruz-Monserrate Z. A High-Fat Diet Activates Oncogenic Kras and COX2 to Induce Development of Pancreatic Ductal Adenocarcinoma in Mice. Gastroenterology 145(6):1449-58, 12/2013. e-Pub 8/2013. PMCID: PMC3873752.
29. Tzeng CW, Balachandran A, Ahmad M, Lee JE, Krishnan S, Wang H, Crane CH, Wolff RA, Varadhachary GR, Pisters PW, Aloia TA, Vauthey JN, Fleming JB, Katz MH. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford) 16(5):430-8, 5/2014. e-Pub 8/2013. PMCID: PMC4008161.
30. Wang H, Foo WC, Rashid A, Wung H, Katz MH, Lee JE, Pisters PW, Wolff RA, Abbruzzese JL, Fleming JB. Loss of phosphatase and tension homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma. Hum Pathol 44(6):1024-30, 6/2013. e-Pub 12/2012.
31. Chatterjee D, Katz MH, Rashid A, Estrella JS, Wang H, Varadhachary GR, Wolff RA, Lee JE, Pisters PW, Abbruzzese JL, Fleming JB, Wang H. Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma. Histopathology 63(6):841-51, 12/2013. e-Pub 9/2013. PMCID: PMC3836824.
32. Shroff S, Rashid A, Wang H, Katz MH, Abbruzzese JL, Fleming JB, Wang H. SOX9: a useful marker for pancreatic ductal lineage of pancreatic neoplasms. Hum Pathol 45(3):456-63, 3/2014. e-Pub 10/2013. PMCID: PMC3945019.
33. Suzuki R, Thosani N, Annangi S, Komarraju A, Irisawa A, Ohira H, Obara K, Fleming JB, Guha S, Bhutani MS. Diagnostic yield of endoscopic retrograde cholangiopancreatography-based cytology for distinguishing malignant and benign intraductal papillary mucinous neoplasm: Systematic review and meta-analysis. Dig Endosc. e-Pub 1/2014. PMID: 24450356.
34. Estrella JS, Li L, Rashid A, Wang H, Katz MH, Fleming JB, Abbruzzese JL, Wang H. Solid pseudopapillary neoplasm of the pancreas: clinicopathologic and survival analyses of 64 cases from a single institution. Am J Surg Pathol 38(2):147-57, 2/2014. PMID: 24418850.
35. Guo R, Overman M, Chatterjee D, Rashid A, Shroff S, Wang H, Katz MH, Fleming JB, Varadhachary GR, Abbruzzese JL, Wang H. Aberrant expression of p53, p21, cyclin D1, and Bcl2 and their clinicopathological correlation in ampullary adenocarcinoma. Hum Pathol 45(5):1015-23, 5/2014. e-Pub 1/2014. PMID: 24746206.
36. Cooper AB, Holmes HM, des Bordes JK, Fogelman D, Parker NH, Lee JE, Aloia TA, Vauthey JN, Fleming JB, Katz MH. Role of Neoadjuvant Therapy in the Multimodality Treatment of Older Patients with Pancreatic Cancer. J Am Coll Surg 219(1):111-20, 7/2014. e-Pub 3/2014. PMID: 24856952.
37. Kang Y, Ling J, Suzuki R, Roife D, Chopin-Laly X, Truty MJ, Chatterjee D, Wang H, Thomas RM, Katz MH, Chiao PJ, Fleming JB. SMAD4 Regulates Cell Motility through Transcription of N-cadherin in Human Pancreatic Ductal Epithelium. PLoS ONE 9(9):e107948, 9/2014. PMCID: PMC4180072.
38. Suzuki R, Kang Y, Li X, Roife D, Zhang R, Fleming JB. Genistein potentiates the antitumor effect of 5-Fluorouracil by inducing apoptosis and autophagy in human pancreatic cancer cells. Anticancer Res 34(9):4685-92, 9/2014. PMCID: PMC4240628.
39. Foo WC, Wang H, Prieto VG, Fleming JB, Abraham SC. Squamoid cystosis of pancreatic ducts: a variant of a newly-described cystic lesion, with evidence for an obstructive etiology. Rare Tumors 6(3):5286, 7/2014. e-Pub 9/2014. PMCID: PMC4178271.
40. Wang H, Estrella JS, Chatterjee D, Katz MH, Rashid A, Wang H, Wolff RA, Varadhachary GR, Lee JE, Pisters PW, Abbruzzese JL, Fleming JB. Hepatobiliary/Pancreas Pathology: SY11-3 PANCREATIC DUCTAL ADENOCARCINOMA: NEOADJUVANT THERAPIES AND PATHOLOGY. Pathology 46 Suppl 2:S25, 10/2014. PMID: 25188109.
41. Roland CL, Yang AD, Katz MH, Chatterjee D, Wang H, Lin H, Vauthey JN, Pisters PW, Varadhachary GR, Wolff RA, Crane CH, Lee JE, Fleming JB. Neoadjuvant Therapy is Associated with a Reduced Lymph Node Ratio in Patients with Potentially Resectable Pancreatic Cancer. Ann Surg Oncol 22(4):1168-75, 4/2015. e-Pub 10/2014. PMID: 25352267.
42. Hiroshima Y, Maawy AA, Katz MH, Fleming JB, Bouvet M, Endo I, Hoffman RM. Selective efficacy of zoledronic acid on metastasis in a patient-derived orthotopic xenograph (PDOX) nude-mouse model of human pancreatic cancer. J Surg Oncol 111(3):311-5, 3/2015. e-Pub 11/2014. PMID: 25394368.
43. Thomas RM, Truty MJ, Kim M, Kang Y, Zhang R, Chatterjee D, Katz MH, Fleming JB. The Canary in the Coal Mine: The Growth of Patient-Derived Tumorgrafts in Mice Predicts Clinical Recurrence after Surgical Resection of Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. e-Pub 11/2014. PMID: 25404477.
44. Cooper AB, Slack R, Fogelman D, Holmes HM, Petzel M, Parker N, Balachandran A, Garg N, Ngo-Huang A, Varadhachary G, Evans DB, Lee JE, Aloia T, Conrad C, Vauthey JN, Fleming JB, Katz MH. Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer. Ann Surg Oncol. e-Pub 12/2014. PMID: 25519927.
45. Li X, Truty MA, Kang Y, Chopin-Laly X, Zhang R, Roife D, Chatterjee D, Lin E, Thomas RM, Wang H, Katz MH, Fleming JB. Extracellular lumican inhibits pancreatic cancer cell growth and is associated with prolonged survival after surgery. Clin Cancer Res 20(24):6529-40, 12/2014. e-Pub 10/2014. PMCID: PMC4268437.
46. Kang Y, Zhang R, Suzuki R, Li SQ, Roife D, Truty MJ, Chatterjee D, Thomas RM, Cardwell J, Wang Y, Wang H, Katz MH, Fleming JB. Two-dimensional culture of human pancreatic adenocarcinoma cells results in an irreversible transition from epithelial to mesenchymal phenotype. Lab Invest 95(2):207-22, 2/2015. e-Pub 12/2014. PMID: 25485535.
47. Koay EJ, Baio FE, Ondari A, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Zhang J, Court L, Bhosale PR, Tamm EP, Qayyum A, Crane CH, Javle M, Katz MH, Gottumukkala VN, Rozner MA, Shen H, Lee JE, Wang H, Chen Y, Plunkett W, Abbruzzese JL, Wolff RA, Maitra A, Ferrari M, Varadhachary GR, Fleming JB. Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. Phys Biol 11(6):065002, 2014. e-Pub 11/2014. PMCID: PMC4266401.
48. Suetsugu A, Katz M, Fleming J, Truty M, Thomas R, Saji S, Moriwaki H, Bouvet M, Hoffman RM. Non-invasive fluorescent-protein imaging of orthotopic pancreatic-cancer-patient tumorgraft progression in nude mice. Anticancer Res 32(8):3063-7, 8/2012. PMID: 22843874.

Invited Articles

1. Kim MP, Evans DB, Vu TM, Fleming JB. The recognition and surgical management of heritable lesions of the pancreas. Surg Oncol Clin N Am 18(1):99-119, 1/2009. PMID: 19056044.
2. Thomas RM, Fleming JB. MicroRNA dissects out dangerous pancreatic cysts from all the rest. Clin Cancer Res 18(17):4482-4, 9/2012. PMID: 22919002.


1. Ling YK, Fournier KF, Babiera GV, Grubbs EG, Wagner JL, Hogue SK, Fleming JB, You YN. The educational impact of a 2-week surgical oncology rotation for third-year medical students: A prospective study. Presented at the Academic Surgical Congress 2012 Annual Meeting (#ASC20120747). Submitted.
2. Jayakumar A, Radjendirane V, Fleming JB, Kang Y, Rusin A, Zielinski R, Skora S, Fokt I, Priebe W. Status of STAT3, STAT5, and NF-kB in pancreatic cancer cell lines, small molecule inhibitors, and potential clinical implications. Am Assoc for Ca Resch (#2946). Submitted.
3. Wang H, Estrella JS, Chatterjee D, Katz MH, Rashid A, Wang H, Wolff RA, Varadhachary GR, Lee JE, Pisters PW, Abbruzzese JL, Fleming JB. Hepatobiliary/Pancreas Pathology: SY11-3 PANCREATIC DUCTAL ADENOCARCINOMA: NEOADJUVANT THERAPIES AND PATHOLOGY. Pathology(Suppl 2):S25, 10/2014. PMID: 25188109.
4. Chang Z, Ju H, Ling J, Zhuang Z, Li Z, Wang H, Fleming JB, Freeman JW, Yu D, Huang P, Chiao PJ. Cooperativity of oncogenic K-ras and downregulated p16/INK4A in human pancreatic tumorigenesis. PLoS One. In Press. PMCID: PMCPMC4100754.

Book Chapters

1. Kim MP, Evans DP, Vu TM, Fleming JB. The Recognition and Surgical Management of Heritable Lesions of the Pancreas. In: Surgical Oncology Clinics of North America. 18, 1. W.B. Saunders: Philadelphia, PA, 99-119, ix. DOI: 10.1016/j.soc.2008.09.001, 2009.

Books (edited and written)

1. Abbott DE, Fleming JB. Ed(s) Abbott DE, Fleming JB. Complex General Surgical Oncology: a Case-Based Approach. 1. Future Medicine, Ltd: Albert Place, London,, e-Book 2013.

Grant & Contract Support

Title: Ex-Vivo Expansion of Small-Volume Tumor Samples
Funding Source: UT MD Anderson Cancer Center Moonshot Knowledge Gap Proposal
Role: Principal Investigator
Duration: 7/1/2013 - 8/31/2014
Title: Intraoperative Gemcitabine for Resectable Adenocarcinoma of the Pancreas: A Pharmacokinetic Clinical Trial
Funding Source: NIH/NCI
Role: Mentor
Principal Investigator: Truty MJ
Duration: 6/30/2011 - 6/30/2012
Title: Tissue pharmacokinetics of intraoperative gemcitabine in resectable PC: A Novel Preoperative Platform in Pancreatic Cancer for Mechanistic Studies
Funding Source: Lustgarten Foundation for Pancreatic Cancer Research
Role: Co-Principal Investigator
Principal Investigator: Varadhachary GR
Duration: 5/1/2011 - 10/31/2014
Title: Expression of TGFBR II or IGFBP-3 and the Effectiveness of TGFB/SMAD Pathway Targeted Therapy Human Pancreatic Cancer
Funding Source: ImClone Systems, LLC
Role: Principal Investigator
Duration: 9/1/2010 - 7/6/2014

Last updated: 6/5/2015